Union Health Minister Mansukh Mandaviya announced on Tuesday that India has approved two new COVID-19 vaccines namely Covovax and Corbevax. In addition to this, an anti-viral drug, Molnupiravir, has also been approved for restricted use in an emergency situation.

'It's a hat-trick!': India approves 2 new Covid vaccines and 1 antiviral drug in a day

In a significant move, India has given emergency use authorisation approval to two more COVID-19 vaccines Covovax and Corbevax and an anti-viral drug Molnupiravir.

India approves 2 more COVID-19 vaccines and an anti-covid pill Molnupiravir

US Food and Drug Administration approved molnupiravir, an anti-Covid pill developed by Merck, as effective against the deadly virus. However, the recent analysis shows a lower efficacy rate than a previous estimate.

New analysis reveals Merck's Covid-19 pill, Molnupiravir, has lower efficacy

United Kingdom on Thursday became the first country in the world to approve a pill treatment for Covid-19. Developed by Merck and Ridgeback Biotherapeutics the antiviral is called "molnupiravir".

World's first pill to treat Covid gets approval in UK. Here's all you need to know

US drugmaker Merck applied for emergency use authorisation in the United States for its pill to fight against coronavirus. The company had claimed that molnupiravir reduced hospitalisations by 50 per cent.

Merck seeks US FDA's authorisation for COVID-19 pill

Molnupiravir, an antiviral drug originally developed to treat influenza reduces hospitalisation and death from Covid-19 by 50% in patients recently infected with the virus, early trial results suggest. Watch this report for more details.

Molnupiravir: New drug to fight against COVID, cuts risk of death by 50%

India's Hetero Labs said on Friday it sought an emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.

India's Hetero seeks emergency use nod for Merck's COVID-19 drug

Amid large scale vaccination in the country, the US government announced it will procure 1.7 million doses of antiviral treatment molnupiravir for coronavirus treatment from Merck.

US to procure 1.7 million courses of molnupiravir coronavirus pills

A new antiviral oral drug called Molnupiravir has been appeared to stop the transmission of SARS-CoV-2 in a single day or 24 hours. Results of the exploration by researchers at the Institute of Biomedical Sciences, Georgia State University, have been distributed in the diary Nature Microbiology.

Molnupiravir: New antiviral oral drug shown to stop COVID-19 spread in 24 hours

molnupiravir

Molnupiravir, News on Molnupiravir, stories on Molnupiravir, articles on Molnupiravir, Molnupiravir stories at Wion, Molnupiravir news, Molnupiravir latest news